ZA95463B - Use of interleukin-12 to prevent graft-versus-host disease - Google Patents

Use of interleukin-12 to prevent graft-versus-host disease

Info

Publication number
ZA95463B
ZA95463B ZA95463A ZA95463A ZA95463B ZA 95463 B ZA95463 B ZA 95463B ZA 95463 A ZA95463 A ZA 95463A ZA 95463 A ZA95463 A ZA 95463A ZA 95463 B ZA95463 B ZA 95463B
Authority
ZA
South Africa
Prior art keywords
interleukin
versus
host disease
prevent graft
prevent
Prior art date
Application number
ZA95463A
Other languages
English (en)
Inventor
Megan Sykes
Stanley F Wolf
Original Assignee
Genetics Inst
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Gen Hospital Corp filed Critical Genetics Inst
Publication of ZA95463B publication Critical patent/ZA95463B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA95463A 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease ZA95463B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ZA95463B true ZA95463B (en) 1995-09-27

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95463A ZA95463B (en) 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease

Country Status (14)

Country Link
US (2) US5573764A (fr)
EP (1) EP0739212B1 (fr)
JP (1) JP3825043B2 (fr)
AT (1) ATE215380T1 (fr)
AU (1) AU698410B2 (fr)
CA (1) CA2181568C (fr)
DE (1) DE69526206T2 (fr)
DK (1) DK0739212T3 (fr)
ES (1) ES2179096T3 (fr)
IL (1) IL112373A (fr)
PT (1) PT739212E (fr)
TW (1) TW349021B (fr)
WO (1) WO1995019786A1 (fr)
ZA (1) ZA95463B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
WO1997016203A1 (fr) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Procedes d'administration d'il-12
CA2268276A1 (fr) * 1996-10-18 1998-04-30 Jeff Nordstrom Expression de genes, systemes d'apport et utilisations
EP0956301A2 (fr) * 1996-10-18 1999-11-17 Valentis Inc. Expression du gene il-12, systemes d'apport et utilisations
WO1998034635A1 (fr) * 1997-02-07 1998-08-13 The Wistar Institute Procedes et compositions pour inhiber la production d'interleukine 12
DE69825395T2 (de) * 1997-05-16 2005-01-13 Toray Industries, Inc. Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
EP1516630A3 (fr) * 1997-10-31 2006-05-03 Wyeth Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20040241153A1 (en) * 2001-08-31 2004-12-02 Fowler Daniel H. Methods of generating human cd4+ th1 cells
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
RU2484132C2 (ru) * 2007-10-08 2013-06-10 Интрексон Корпорейшн Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
CA2800348C (fr) 2010-05-18 2020-07-21 Lena A. Basile Formulations d'il-12 pour la stimulation de l'hematopoiese
US9925246B2 (en) 2011-06-13 2018-03-27 Neumedicines, Inc. Mitigation of cutaneous injury with IL-12
US20140178335A1 (en) 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
CA2850575C (fr) * 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combinaison medicamenteuse comprenant de l'il-12 et un agent de blocage de molecules inhibitrices des lymphocytes t pour une therapie anti-tumorale
US9616106B2 (en) 2012-01-18 2017-04-11 Neumedicines, Inc. IL-12 for radiation protection and radiation-induced toxicity mitigation
WO2013158959A1 (fr) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions et procédés pour le traitement de la maladie du greffon contre l'hôte
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Engineered il-12 and il-23 polypeptides and uses thereof
EP4228610A1 (fr) * 2020-10-13 2023-08-23 Kriya Therapeutics, Inc. Constructions de vecteurs viraux pour l'apport d'acides nucléiques codant pour des cytokines et leurs utilisations pour le traitement du cancer
EP4419545A4 (fr) 2021-10-20 2025-10-22 Synthekine Inc Cytokines fc hétérodimères et leurs utilisations
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131524A1 (fr) * 1992-03-04 1993-09-16 Maria-Grazia Roncarolo Utilisation de l'interleukine-10 pour eliminer la reaction du greffon contre l'hote
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
AU698410B2 (en) 1998-10-29
ATE215380T1 (de) 2002-04-15
CA2181568A1 (fr) 1995-07-27
AU1687595A (en) 1995-08-08
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
DE69526206D1 (de) 2002-05-08
JP3825043B2 (ja) 2006-09-20
ES2179096T3 (es) 2003-01-16
EP0739212B1 (fr) 2002-04-03
PT739212E (pt) 2002-08-30
IL112373A (en) 2006-08-01
IL112373A0 (en) 1995-03-30
EP0739212A1 (fr) 1996-10-30
WO1995019786A1 (fr) 1995-07-27
TW349021B (en) 1999-01-01
JPH09508371A (ja) 1997-08-26
US5573764A (en) 1996-11-12
CA2181568C (fr) 2007-09-18
US5756085A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
IL112373A0 (en) Use of interleukin-12 to prevent graft versus host disease
SG49658A1 (en) Treatment of condition and disease
EP0441119A3 (en) The use of l-arginine in the treatment of hypertension and other vascular disorders
UA32429C2 (uk) Засіб для лікування нетримання сечі
GB9320747D0 (en) A compress for use in the cold and/or hot treatment of an injury
PL326653A1 (en) Application of epinastin in pain relieving treatments
AU1577792A (en) Implantation tissue and treatment and use methods
ZA931174B (en) Treatment of disease employing hyaluronic acid and nsaids.
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
IL102106A0 (en) Arylethers,their manufacture and methods of treatment
PL324750A1 (en) Expressive construct p16 and posiibility of using it in treating carcinomas
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
ZA935575B (en) Therapeutic agent and its use.
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
NO913054L (no) Vaginal behandlingsprosess og innretning med dusj.
EP0745597A3 (fr) Indanylpipérazines ou homopipérazines mélatonergiques
GB9616549D0 (en) Therapeutic product and its use
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
张钦 et al. EJACULATIO DEFICIENS TREATED WITH ACUPUNCTURE REPORT OF 110 CASES
EP0596937A4 (fr) Plasmalopsychosines et plasmalocerebrosides et procedes de traitement de maladies neuronales les utilisant.
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
GB9005605D0 (en) Treatment of sleep apnoea
ZA963998B (en) 3,4-Disubstituted-phenylsulphonamides and their therapeutic use